ReviewFrontiers in immunology2021
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Camille Keenan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
112 papers cite itlatest 60 shown
this paperpooled ittrialcites it